On December 23, 2021, the FDA issued an EUA for molnupiravir for the treatment of mild to moderate COVID 19 in eligible high-risk patients for whom alternative COVID - 19 treatment options are not accessible or clinically appropriate. Molupiravir is a nucleoside analogue that inhibits SARS-CoV-2 by viral mutagenesis. At this time, Molnupiravir is NOT authorized for individuals less than 18 years of age, for hospitalized patients, for use for longer than 5 days, or for individuals who are pregnant/and or breastfeeding.
Prescribers must comply with requirements of the US Food and Drug Administration's Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir and with the State of Michigan Priority Eligibility Criteria and prescribing requirements for this medication. Patients must have tested positive for SARS-CoV-2.
Molnupiravir is indicated for the treatment of mild-to-moderate (COVID-19) in adults (18 years of age), and
who meet the current Priority Eligibility Criteria.
Dosing and Administration of Molnupiravir (see full Fact Sheet for Healthcare Providers)
Dosage Forms of Molnupiravir
Warning and Precautions for Molnupiravir
Contraindications for Molnupiravir
All adverse reactions and medication errors must be reported to the FDA using FDA form 3500 FDA ADVERSE REACTIONS.